Form 4: Intellia Therapeutics CFO Edward J. Dulac III Reports Stock and Option Transactions

EVP and CFO of Intellia Therapeutics, Edward J. Dulac III, reports acquisition of restricted stock units and stock options, as well as disposal of common stock.

Summary

• On March 1, 2025, Edward J. Dulac III, the EVP and CFO of Intellia Therapeutics, reported transactions involving Intellia Therapeutics, Inc. [NTLA] securities.
• Dulac acquired 47,200 shares of common stock through restricted stock units at a price of $0.
• Following the transaction, Dulac directly owns 113,524 shares of common stock.
• Dulac also acquired options to purchase 67,429 shares of common stock at an exercise price of $10.09, exercisable from March 1, 2025, with vesting starting January 1, 2026.
• The options expire on February 28, 2035.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it is a standard regulatory filing detailing stock transactions. The acquisition of shares and options could be seen as a positive, but the disposal of shares tempers this.

Positives

• The acquisition of restricted stock units and stock options by the CFO could be seen as a positive sign, indicating confidence in the company's future performance.

Negatives

• The disposal of common stock may be interpreted negatively, although the specific reasons for the disposal are not provided.

Risks

• The vesting schedule of the stock options means that the CFO's incentives are aligned with the long-term performance of the company, but there is a risk that the options may not become fully vested if the CFO leaves the company before the vesting date.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the trading activities of company executives.

Stakeholder Impact

• Shareholders may be interested in the trading activity of company executives as it can provide insights into their confidence in the company's prospects.

Key Dates